Why Osiris Therapeutics Inc. Shares Tanked

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Osiris Therapeutics (NASDAQ: OSIR  )   -- a company that market stem cell-based therapies to treat inflammatory, orthopedic, and wound healing markets -- dipped as much as 17% after announcing the resignation of its president and CEO, C. Randal Mills.

So what: According to the press release, C. Randal Mills will be stepping down as president and CEO for personal reasons, but will remain on board as a strategic adviser for the company. Stepping into the new role of CEO will be current chief operating officer Lode Debrabrandere pending approval of Osiris' board of directors.

Now what: Any time there is a transition at the head of a company, there is an amount of uncertainty created that can work against the stock price and shareholders. The fear from investors is that C. Randal Mills finally delivered Osiris into profitable territory, and his departure could shift Osiris off that path. While I'm certainly disappointed to see Mills leave, Osiris still looks well-positioned to benefit from its diabetic wound-healing treatment Grafix. With a full-year of profitable (albeit a minimal profit) expected next year, I would contend that today's dip may represent an intriguing buying opportunity for more risk-willing and biotech-savvy investors.

Another intriguing opportunity you won't want to miss
The market stormed out to huge gains across 2013, leaving investors on the sidelines burned. However, opportunistic investors can still find huge winners. The Motley Fool's chief investment officer has just hand-picked one such opportunity in our new report: "The Motley Fool's Top Stock for 2014." To find out which stock it is and read our in-depth report, simply click here. It's free!


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2750766, ~/Articles/ArticleHandler.aspx, 4/16/2014 11:51:54 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement